MDDI Online | Medical Device and Diagnostics Industry

0
17

Removing the CyPass Micro-Stent from the market is in patients’ best interests, and is “the right thing to do,” said Alcon’s chief medical officer, after five-year data revealed a higher rate of cell loss compared to patients who had cataract surgery alone.

LEAVE A REPLY

Please enter your comment!
Please enter your name here